Bispecific antibodies in cancer immunotherapy.,Current Opinion in Biotechnology

当前位置： X-MOL 学术 › Curr. Opin. Biotech. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Bispecific antibodies in cancer immunotherapy.
Current Opinion in Biotechnology ( IF 7.1 ) Pub Date : 2019-12-13 , DOI: 10.1016/j.copbio.2019.11.020
Christoph Rader ₁

Affiliation

Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening their therapeutic utility from hematologic to solid malignancies, and generating T-biAbs in situ. In cancer immunotherapy, T-biAbs are facing fierce competition with chimeric antigen receptor T cells (CAR-Ts), a battle for clinical and commercial viability that will be closely watched. However, innovative combinations of T-biAbs and CAR-Ts have also transpired. NK-cell engaging biAbs (NK-biAbs) are reemerging as an alternative that addresses liabilities of T-biAbs. Beyond NK-biAbs, other biAbs designed to recruit cellular and molecular components of the innate immune system will be covered in this reflection on new tools, technologies, and targets.

中文翻译：

癌症免疫治疗中的双特异性抗体。

在基于抗体的癌症疗法中，双特异性抗体 (biAb) 在开拓性 T 细胞结合 biAb (T-biAb) blinatumomab 获得监管批准后，在临床前和临床研究中获得了动力。本文讨论的是最近的策略，旨在提高 T-biAb 的效力并减轻其毒性，将其治疗效用从血液学扩展到实体恶性肿瘤，并原位生成 T-biAb。在癌症免疫治疗中，T-biAb 面临着与嵌合抗原受体 T 细胞 (CAR-T) 的激烈竞争，这是一场备受关注的临床和商业可行性之战。然而，T-biAbs 和 CAR-Ts 的创新组合也出现了。与 NK 细胞结合的双抗体 (NK-biAb) 正在重新出现，作为解决 T-biAb 缺陷的替代方案。除了 NK-biAbs，

更新日期：2020-04-20

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11